Rise Advisors’s Larimar Therapeutics LRMR Stock Holding History

Rise Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-381	Closed	-$1.23K	–	862
2025 Q3	$1.23K	Buy	381 +148	+64%	+$555	﹤0.01%	1250
2025 Q2	$673	Buy	+233	New	+$539	﹤0.01%	1356

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rise Advisors's LRMR Position: Q4 2025 in Review

Rise Advisors sold out of Larimar Therapeutics (LRMR) in Q4 2025, closing a stake of 381 shares — an estimated $1.23K sold.

Rise Advisors first reported a position in LRMR in Q2 2025 and held it in 2 quarters. The position peaked at $1.23K in Q3 2025. 136 funds tracked by Wall St. Rank hold LRMR as of Q4 2025.

Rise Advisors reported no remaining Larimar Therapeutics position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 381 Larimar Therapeutics shares in Q4 2025, an estimated $1.23K.
Rise Advisors first reported a position in Larimar Therapeutics in Q2 2025 and held it in 2 quarters.
Rise Advisors's Larimar Therapeutics position peaked at $1.23K in Q3 2025.
136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.